- Home
- VRXA vs GALT Comparison
VRXA vs GALT Comparison
Compare VRXA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRXA | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.0M | 297.0M |
| IPO Year | 2025 | 2008 |
Fundamental Metrics
Financial Performance| Metric | VRXA | GALT |
|---|---|---|
| Price | $1.65 | $3.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 380.8K | 323.5K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $2.03 |
| 52 Week High | $4.50 | $7.13 |
Technical Indicators
Market Signals| Indicator | VRXA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 49.98 |
| Support Level | $1.27 | $2.74 |
| Resistance Level | $1.99 | $4.35 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 52.05 | 28.07 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.